Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.34
+0.34000.57%
Post-market: 60.340.00000.00%17:58 EDT
Volume:2.32M
Turnover:140.33M
Market Cap:11.68B
PE:402.27
High:61.15
Open:60.37
Low:59.92
Close:60.00
Loading ...

Why Incyte (INCY) Stock Is Nosediving

StockStory
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop

MT Newswires Live
·
18 Mar

Incyte Is Today's Worst S&P 500 Stock. Here's Why. -- Barrons.com

Dow Jones
·
17 Mar

Incyte Down Over 9%, on Pace for Largest Percent Decrease Since April 2018 -- Data Talk

Dow Jones
·
17 Mar

Incyte Corp Shares Down 11.5% After Skin Disease Drug Fails to Impress in Late-Stage Studies

THOMSON REUTERS
·
17 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, Incyte

Reuters
·
17 Mar

BUZZ-Incyte falls after late-stage data from experimental skin disease drug

Reuters
·
17 Mar

Incyte's Positive Results Not Positive Enough -- Market Talk

Dow Jones
·
17 Mar

Buy Rating for Incyte’s Povorcitinib Despite Mixed Trial Results, Highlighting Potential in Biologic-Experienced Subgroups

TIPRANKS
·
17 Mar

Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa

Dow Jones
·
17 Mar

Incyte Shares Down 14.5% Premarket; Co's Skin Disease Drug Meets Main Goal in Two Late-Stage Studies

THOMSON REUTERS
·
17 Mar

Incyte's skin disease drug meets main goal in two late-stage studies

Reuters
·
17 Mar

Incyte Corp - Favorable Safety Profile With No Safety Concerns

THOMSON REUTERS
·
17 Mar

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

THOMSON REUTERS
·
17 Mar

Incyte Corp - Statistically Significant Results in Both Stop-Hs1 and Stop-Hs2 Studies

THOMSON REUTERS
·
17 Mar